Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- TNDM +12.5%, TTMI +11.9%, CNMD +10.4%, AAON +9.6%, ALGN +9.1%, MSFT +9%, GH +8.6%, CVS +8.3%, WHD +8%, NTGR +8%, ALKT +7.9%, IRT +7.8%, W +7.8%, CTOS +7.7%, UIS +7.3%, FORM +7%, RYI +6.9%, META +6%, SPOK +5.9%, CWEN +5.6% (also increases dividend), UPBD +5.5%, DLX +5.1%, CARR +4.9%, WAY +4.6%, BCYC +4.6%, PWR +4.6%, HOOD +4.1% (also increases buyback program by $500 mln), ESAB +4.1%, MAX +3.9%, AEIS +3.7%, GTLS +3.7%, CTSH +3.6%, MCW +3.5%, CRK +3.4%, ACT +3.4% (also authorizes new $350 mln share repurchase program, also increases dividend), MGM +3.3%, CWAN +3.3%, STNG +3.3%, HWM +3.3%, BE +3.2%, COMM +3.2%, AGIO +3.1%, VNT +3.1%, GM +2.9%, ENVX +2.7%, BAX +2.7%, CNXN +2.6% (also increases share repurchase authorization by $50 mln), APTV +2.6%, TS +2.5%, MEOH +2.2%, FMC +2.1%, MYRG +2%, AXS +1.9%, WCC +1.9%, ALB +1.8%, NFG +1.8%, TSLX +1.7%, BPMC +1.7%, KKR +1.6%, LAUR +1.6%, CHRW +1.5%, TNC +1.4%, CCJ +1.3%, HAYW +1.3%, HLF +1%, GTX +1%
Other news:
- OLO +8.1% (exploring a potential sale, according to Bloomberg)
- NVDA +4.9% (positive AI infrastructure comments from META; also MSFT provided bullish Azure guidance)
- NVO +4.2% (NEJM publishes Phase 3 trial of semaglutide)
- BLKB +4% (names new CFO)
- AMZN +3.7% (investing $4+ bln to expand rural delivery network)
- CRK +3.4% (BKV to develop carbon capture projects at two of CRK's facilities)
- IONQ +3.1% (demonstrates quantum-enhanced applications advancing AI)
- ESEA +2.6% (to delay 20-F filing)
- XPEV +2.6% (April Deliveries)
- FFAI +2.4% (Issues Statement on Potential Illegal Short Selling and Online Infringement to Protect Interests of Stockholders)
- KREF +2.1% (files for $750 mln mixed securities shelf offering; files for offering by selling shareholders)
- FOUR +2.1% (Upsize and Pricing of Offering of Series A Mandatory Convertible Preferred Stock)
- NIO +1.5% (April Deliveries)
Analyst comments:
- CWH +3.8% (upgraded to Overweight from Neutral at JPMorgan)
- NOW +2.6% (upgraded to Buy from Hold at Truist)
- HUM +1.2% (upgraded to Outperform from Market Perform at Raymond James)